840 related articles for article (PubMed ID: 12107550)
41. Examination of purported probes of human CYP2B6.
Ekins S; VandenBranden M; Ring BJ; Wrighton SA
Pharmacogenetics; 1997 Jun; 7(3):165-79. PubMed ID: 9241656
[TBL] [Abstract][Full Text] [Related]
42. Effects of arachidonic acid, prostaglandins, retinol, retinoic acid and cholecalciferol on xenobiotic oxidations catalysed by human cytochrome P450 enzymes.
Yamazaki H; Shimada T
Xenobiotica; 1999 Mar; 29(3):231-41. PubMed ID: 10219964
[TBL] [Abstract][Full Text] [Related]
43. Identification of cytochrome P450 isoforms involved in citalopram N-demethylation by human liver microsomes.
Kobayashi K; Chiba K; Yagi T; Shimada N; Taniguchi T; Horie T; Tani M; Yamamoto T; Ishizaki T; Kuroiwa Y
J Pharmacol Exp Ther; 1997 Feb; 280(2):927-33. PubMed ID: 9023308
[TBL] [Abstract][Full Text] [Related]
44. Metabolism of 2,5-bis(trifluoromethyl)-7-benzyloxy-4-trifluoromethylcoumarin by human hepatic CYP isoforms: evidence for selectivity towards CYP3A4.
Renwick AB; Lewis DF; Fulford S; Surry D; Williams B; Worboys PD; Cai X; Wang RW; Price RJ; Lake BG; Evans DC
Xenobiotica; 2001 Apr; 31(4):187-204. PubMed ID: 11465405
[TBL] [Abstract][Full Text] [Related]
45. Identification of three cytochrome P450 isozymes involved in N-demethylation of citalopram enantiomers in human liver microsomes.
Rochat B; Amey M; Gillet M; Meyer UA; Baumann P
Pharmacogenetics; 1997 Feb; 7(1):1-10. PubMed ID: 9110356
[TBL] [Abstract][Full Text] [Related]
46. Inhibition of cytochrome P450 enzymes involved in ketamine metabolism by use of liver microsomes and specific cytochrome P450 enzymes from horses, dogs, and humans.
Mössner LD; Schmitz A; Theurillat R; Thormann W; Mevissen M
Am J Vet Res; 2011 Nov; 72(11):1505-13. PubMed ID: 22023129
[TBL] [Abstract][Full Text] [Related]
47. In vitro inhibition of cytochrome P450 enzymes in human liver microsomes by a potent CYP2A6 inhibitor, trans-2-phenylcyclopropylamine (tranylcypromine), and its nonamine analog, cyclopropylbenzene.
Taavitsainen P; Juvonen R; Pelkonen O
Drug Metab Dispos; 2001 Mar; 29(3):217-22. PubMed ID: 11181487
[TBL] [Abstract][Full Text] [Related]
48. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation.
Code EL; Crespi CL; Penman BW; Gonzalez FJ; Chang TK; Waxman DJ
Drug Metab Dispos; 1997 Aug; 25(8):985-93. PubMed ID: 9280407
[TBL] [Abstract][Full Text] [Related]
49. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N,N-dimethylamine) metabolites in human liver microsomes.
Bae SK; Cao S; Seo KA; Kim H; Kim MJ; Shon JH; Liu KH; Zhou HH; Shin JG
Drug Metab Dispos; 2008 Aug; 36(8):1679-88. PubMed ID: 18474675
[TBL] [Abstract][Full Text] [Related]
50. N,N-diethyl-2-[4-(phenylmethyl)phenoxy] ethanamine (DPPE) a chemopotentiating and cytoprotective agent in clinical trials: interaction with histamine at cytochrome P450 3A4 and other isozymes that metabolize antineoplastic drugs.
Brandes LJ; Queen GM; LaBella FS
Cancer Chemother Pharmacol; 2000; 45(4):298-304. PubMed ID: 10755318
[TBL] [Abstract][Full Text] [Related]
51. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes.
Rifkind AB; Lee C; Chang TK; Waxman DJ
Arch Biochem Biophys; 1995 Jul; 320(2):380-9. PubMed ID: 7625847
[TBL] [Abstract][Full Text] [Related]
52. Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
Ekhart C; Doodeman VD; Rodenhuis S; Smits PH; Beijnen JH; Huitema AD
Br J Clin Pharmacol; 2009 Jan; 67(1):50-60. PubMed ID: 19076156
[TBL] [Abstract][Full Text] [Related]
53. Further assessment of 17alpha-ethinyl estradiol as an inhibitor of different human cytochrome P450 forms in vitro.
Chang SY; Chen C; Yang Z; Rodrigues AD
Drug Metab Dispos; 2009 Aug; 37(8):1667-75. PubMed ID: 19454483
[TBL] [Abstract][Full Text] [Related]
54. Metabolism of theophylline by cDNA-expressed human cytochromes P-450.
Ha HR; Chen J; Freiburghaus AU; Follath F
Br J Clin Pharmacol; 1995 Mar; 39(3):321-6. PubMed ID: 7619675
[TBL] [Abstract][Full Text] [Related]
55. CYP3A4 is the major CYP isoform mediating the in vitro hydroxylation and demethylation of flunitrazepam.
Hesse LM; Venkatakrishnan K; von Moltke LL; Shader RI; Greenblatt DJ
Drug Metab Dispos; 2001 Feb; 29(2):133-40. PubMed ID: 11159802
[TBL] [Abstract][Full Text] [Related]
56. Identification of the human cytochrome P450 enzymes involved in the in vitro metabolism of artemisinin.
Svensson US; Ashton M
Br J Clin Pharmacol; 1999 Oct; 48(4):528-35. PubMed ID: 10583023
[TBL] [Abstract][Full Text] [Related]
57. In vitro metabolism of quinidine: the (3S)-3-hydroxylation of quinidine is a specific marker reaction for cytochrome P-4503A4 activity in human liver microsomes.
Nielsen TL; Rasmussen BB; Flinois JP; Beaune P; Brosen K
J Pharmacol Exp Ther; 1999 Apr; 289(1):31-7. PubMed ID: 10086984
[TBL] [Abstract][Full Text] [Related]
58. Human liver microsomal diazepam metabolism using cDNA-expressed cytochrome P450s: role of CYP2B6, 2C19 and the 3A subfamily.
Ono S; Hatanaka T; Miyazawa S; Tsutsui M; Aoyama T; Gonzalez FJ; Satoh T
Xenobiotica; 1996 Nov; 26(11):1155-66. PubMed ID: 8948091
[TBL] [Abstract][Full Text] [Related]
59. Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
Xing J; Kirby BJ; Whittington D; Wan Y; Goodlett DR
Drug Metab Dispos; 2012 Sep; 40(9):1757-64. PubMed ID: 22679214
[TBL] [Abstract][Full Text] [Related]
60. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9.
Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ
Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
